Chengdu Olymvax Biopharmaceuticals Inc.’s Net Profit Dropped 14.8% in First Half of 2023

Chengdu Olymvax Biopharmaceuticals Inc. (成都欧林生物科技股份有限公司) (688319.SH) reported a net profit of 26.4 million yuan in the first half of 2023, down 14.8% year-on-year.

Meanwhile, the company posted 233.2 million yuan in revenue, up 0.2% year-on-year.

At the end of the reporting period, it had 1.5 billion yuan in total assets and 558.7 million yuan in total liabilities, with a liability-to-asset ratio of 37.7%.